Insulet Corporation has announced its strategic plan and innovation roadmap aimed at extending its leadership in the global automated insulin delivery (AID) market for type 1 and type 2 diabetes. The company plans to drive growth within a total addressable market of over $30 billion by accelerating innovation, advancing clinical practice, expanding access, and generating demand through commercial initiatives. Insulet highlighted its unique product form factor, pay-as-you-go pharmacy model, advanced automated manufacturing, and supply chain capabilities as key competitive advantages. Financial projections for 2025-2028 include a compound annual revenue growth rate of approximately 20% at constant currency rates and an annual expansion of adjusted operating margin by about 100 basis points, supported by ongoing Omnipod adoption and geographic expansion. The company also introduced a next-generation innovation pipeline targeting further transformation in diabetes care.